TORONTO, April 03, 2018 (GLOBE NEWSWIRE) — MPX Bioceutical Corporation (“MPX” or the “Company”) (CSE:MPX) (OTC:MPXEF) has reported that its managed Arizona assets have recorded their best revenue month in March with sales of cannabis and cannabis concentrates hitting the US$4.0 (CDN$5.2) million mark for the first time.
“We have been accumulating assets and expanding capacity in Arizona for the past 15 months and we are now seeing those efforts producing significant revenue expansion with an annualized revenue run-rate in excess of CDN$60 million”, says W. Scott Boyes, MPX’s Chairman, President and CEO. “With three operating dispensaries, two cultivation and two concentrate production facilities under management in the Greater Phoenix area, MPX is providing high quality cannabis-based medicines to an ever-increasing number of patients. The Arizona Department of Health Services (“AZDHS”) has reported that the number of card-holding cannabis patients increased by 33% during the 12 months ending February 2018, so the market size continues to expand, and we are working diligently to be able to service that growth.”Beth Stavola, COO and President of MPX’s U.S. operations, adds “With our fourth dispensary opening soon in the Apache Junction suburb and our expanded concentrate production facilities coming on-stream this month, we expect to see our Arizona revenues continue to expand over the next several fiscal quarters. The Arizona program is well-regulated by AZDHS, the patient count continues to grow, the supply and cost of flower and trim for re-sale and concentrate production is excellent and, while the Phoenix area market is increasingly competitive, retail prices and margins remain attractive. This is a great state for MPX to conduct business in.”The above revenue numbers are from assets under management in Arizona only and do not include operations in Nevada or those assets currently being developed in the States of Maryland and Massachusetts. Further

Read More Here...